Lennart Opitz

Transcriptomic signatures of hydroxyurea response in sickle cell disease

Abstract Background Hydroxyurea (HU) has been widely used as a first-line therapy for sickle cell disease (SCD), an autosomal recessive monogenic disorder characterized by abnormal haemoglobin and chronic haemolysis. However, its multiple mechanisms of action, particularly those...